SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Non-Current Assets came in at $135.7 million in Q1 2026, up 521.76% YoY from $21.8 million in Q1 2025, and up 89.09% on a QoQ basis from $71.8 million in Q4 2025.
SAB Biotherapeutics (SABS) Non-Current Assets (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Non-Current Assets data on file, last reported at $135.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 521.76% year-over-year to $135.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.4 million (up 247.84% YoY) and the FY2025 annual result came in at $71.8 million, up 251.7% from the prior year.
- Non-Current Assets climbed to $135.7 million in Q1 2026, from $71.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $135.7 million in Q1 2026 to a low of $20.4 million in Q4 2024.
- A 5-year average of $37.3 million and a median of $26.4 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets plunged 73.89% — and 2026, when it jumped 521.76%.
- Tracing SABS's Non-Current Assets over 5 years: stood at $28.8 million in 2022, then decreased by 13.1% to $25.0 million in 2023, then retreated by 18.5% to $20.4 million in 2024, then soared by 251.7% to $71.8 million in 2025, then soared by 89.09% to $135.7 million in 2026.
- The last three Non-Current Assets figures came in at $135.7 million (Q1 2026), $71.8 million (Q4 2025), and $70.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 130.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130.27 Mn |
| Mar 31, 2026 | 135.69 Mn |
| Dec 31, 2025 | 71.76 Mn |
| Sep 30, 2025 | 70.17 Mn |
| Jun 30, 2025 | 20.82 Mn |
| Mar 31, 2025 | 21.82 Mn |
| Dec 31, 2024 | 20.40 Mn |
| Sep 30, 2024 | 21.26 Mn |
| Jun 30, 2024 | 22.31 Mn |
| Mar 31, 2024 | 24.42 Mn |
| Dec 31, 2023 | 25.03 Mn |
| Sep 30, 2023 | 25.21 Mn |
| Jun 30, 2023 | 26.44 Mn |
| Mar 31, 2023 | 27.64 Mn |
| Dec 31, 2022 | 28.81 Mn |
| Sep 30, 2022 | 30.33 Mn |
| Jun 30, 2022 | 31.40 Mn |
| Mar 31, 2022 | 31.30 Mn |
| Dec 31, 2021 | 30.95 Mn |
| Sep 30, 2021 | 116.16 Mn |